Immunocore Receives FDA Approval for the First Uveal Melanoma Treatment, As Well As the First T-cell Receptor Therapeutics
Uveal Melanoma, an aggressive eye cancer, has proven to be a tough nut to crack for researchers seeking a cure. However, with the approval of a new treatment, those with the disorder will have a better chance of survival. The FDA-approved Immunocore's Kimmtrak (tebentafusp-tabn), the first T-cell receptor therapeutic for unresectable or Metastatic Uveal Melanoma (mUM) treatment.
The FDA approved the infused treatment a month ahead of schedule and five months after regulators in the United States and Europe approved Immunocore's biologics lic...
